Content Type: Commentary & Opinion

Will the New Administration’s FDA Be a Threat or an Opportunity for the Public’s Health?

March 6, 2026

Use of Public Research and Manufacturing Enterprises to Lower Prescription Drug Prices and Increase Innovation

March 6, 2026

Op-Ed: Lessons from Humira on How to Tackle Unjust Extensions of Drug Monopolies with Policy

March 6, 2026

Revising EU Pharmaceutical Legislation: Will It Foster Drug Repurposing?

March 6, 2026

Seeking a Better Paper Trail of Federal Research Funding

March 6, 2026

Patient Assistance Programs-A New Era of Law and Policy

March 6, 2026

Confirmatory Trials of Accelerated Approval Drugs—Will Imposing Fines Reduce Delays?

March 6, 2026

The Patent Trial and Appeals Board: A Target for Prescription Drug Patent Reform?

March 6, 2026

Patent Claim Scope and Biosimilar Competition in the US and EU

March 6, 2026

Invited Commentary on Interventional Pharmacoepidemiology: Origins, Current Status, and Future Possibilities

March 6, 2026

Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa (Reply)

March 6, 2026

State Spending Targets for Prescription Drugs

March 6, 2026